1. Scrip

How CRA’s Diverse Seed-Planting Bore Inclusive Fruit

 
• By Alaric DeArment

The research center went directly to local Black, Latino and Kurdish communities in Nashville, TN, to generate interest in COVID-19 vaccine trials.

Business Growth Concept_1089895325_1200.jpg
How CRA ensured diverse enrollment in two COVID-19 vaccine trials • Source: Shutterstock

While multiple drug makers have received credit for stepping up efforts to improve clinical trial diversity during the pandemic, it is the individual research sites, such as the Nashville, TN-based research firm Clinical Research Associates, Inc., that often do the ground-level legwork, connecting to local communities and building trust.

CRA was one of numerous trial sites that tested Pfizer Inc./BioNTech SE’s Comirnaty vaccine, as well as

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Executives On The Move: Fable Therapeutics Gains CMO From AstraZeneca

Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.